Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Markus MöhlerHong XiaoSteven I BlumElena ElimovaDavid CellaKohei ShitaraJaffer A AjaniYelena Y JanjigianMarcelo GarridoLin ShenKensei YamaguchiTianshu LiuMichael SchenkerRuben KowalyszynArinilda Campos BragagnoliRicardo BrugesVincenzo MontesarchioRoberto A Pazo-CidShannon HunterEric DavenportJinyi WangKaoru KondoMingshun LiLucjan WyrwiczPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.